



PTO/SB/08B(10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 1

Complete if Known

Application Number	09/834,321
Filing Date	April 13, 2001
First Named Inventor	Jeffrey V. Ravetch
Group Art Unit	1644
Examiner Name	Michail A. Belyavskyi
Attorney Docket Number	RFU0001-100 (RU-479)

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
MJB		CLYNES et al., "Inhibitory Fc Receptors Modulate In Vivo Cytotoxicity Against Tumor Targets," <i>Nature Medicine</i> , Vol. 6, No. 4, 2000, pp. 1078-8956.	
		D'AMBROSIO ET AL., "The Ship Phosphate 1-15 Becomes Associated With FcgammaRIIB1 And Is Tyrosine Phosphorylated During Negative Signaling," <i>Immunology Letters</i> , 1996, Vol. 54, No. 2-3, pp. 77-82.	
		LIU et al., "Protein Tyrosine Phosphorylation Triggered By Human Fcgamma-RII," <i>Biochemical And Biophysical Research Communications</i> , Vol. 201, No. 2, pp. 829-834.	
		MURAILLE et al., "The SH2 Domain Containing Inositol 5-Phosphatase SHIP2 Associates To The Immunoreceptor Tyrosine-Based Inhibition Motif Of FcgammaRIIB In B Cells Under Negative Signaling," <i>Immunology Letters</i> , 2000, Vol. 72, No. 1, pp. 7-15.	
MJB		European Search Report dated August 10, 2004 for European Search Report 01 92 6962-	

Examiner
Signature


Date
Considered

5/22/06

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



PTO/SB/08B(07-05)

Approved for use through 07/31/2008. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 1 of 1

Complete if Known

Application Number	09/834,321
Filing Date	April 13, 2001
First Named Inventor	Jeffrey V. Ravetch
Art Unit	1644
Examiner Name	Michail A. Belyavskyi
Attorney Docket Number	RFU0001-100

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
MB		HOUGHTON AN and SCHEINBERG DA, "Monoclonal Antibody Therapies - a 'Constant' Threat to Cancer", NATURE MEDICINE, Vol. 6, No. 4, April 2000, pages 373-374	

Examiner
SignatureDate
Considered

5/22/06

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.